Back to first-pass browser

First-pass extracted concept

AAV immunogenicity

Candidate: concept label1 source documents3 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Evidence Snippets

Emerging Technologies Tackling Adeno-Associated Viruses (AAV) Immunogenicity in Gene Therapy Applications.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1backgroundsupports2025Source 1DOIPubMed

AAV vectors are described as a safe and effective gene therapy delivery system.

Claim 2problem statementsupports2025Source 1DOIPubMed

Immune responses to AAV and the transgene create safety concerns and can make subsequent AAV injections ineffective.

Claim 3problem statementsupports2025Source 1DOIPubMed

Pre-existing neutralizing antibodies or memory T cells against AAV from natural infection are an important barrier that must be overcome.